



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

Date: - 14-11-2025

To,  
**BSE Limited**  
Listing / Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001

**BSE Scrip Code:-544445**

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Respected Stakeholders:

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that the Board of Directors of the Company, at its meeting held on 22 June, 2025 and again at its meeting held on November 14, 2025, has approved the following proposed capacity expansion of manufacturing capacities:

1. Setting up of a Second Manufacturing Unit (Unit II) of Pharmaceuticals and Nutraceuticals Product situated at Plot no W 18-A, MIDC, Addl. Ambernath, Anand Nagar Industrial area, Dist-Thane, Mumbai, Maharashtra 421501.

The details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as **Annexure A** respectively.

Kindly take the above on record.

This disclosure complies with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

**For Asston Pharmaceuticals Limited**

**Rishi Upadhaya**  
**Company Secretary and Compliance Officer**  
**A74324**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi  
Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

**Annexure-A**

The details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are as follows:

<b>S.NO.</b>	<b>PARTICULARS</b>	<b>UNIT OF MEASUREMENT (WoM)</b>	<b>DETAILS</b>
1	Existing Capacity	Tablet per Month	5-6 Crore
2	Existing capacity utilization	Percent (%)	80
3	Total Capacity after proposed addition	Tablet per Month	14-15 Crore
4	Period within which the proposed capacity is to be added	-	Q4- 2025-26
5	Investment Proposed	In Lakhs	600 (Approx)
6	Mode of financing	-	Internal Accruals / Initial Public Offer Proceeds
7	Rationale	-	To meet the captive requirement as well as the growing market demand for our products.

**Note:-** The Existing Capacity is installed at Plot K-50, Near MSEB Sub- Station, Thakur Pada Gaon MIDC, Anandnagar, Ambarnath, Mumbai, Maharashtra 421501

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)